融合自杀基因CDglyTK治疗喉癌的体外实验研究(英文)  

Study of treating laryngeal cancer with suicide fusion gene CDglyTK in vitro

作　　者：唐瑶云[1] 徐婧[1] 刘建平[2] 郑颂扬[2] 赵素萍[1] 张俊毅[1] 肖健云[1] 

机构地区：[1]中南大学湘雅医院耳鼻咽喉,湖南长沙410008 [2]中南大学现代分析测试中心,湖南长沙410008

出　　处：《中国现代医学杂志》2006年第12期1766-1771,共6页China Journal of Modern Medicine

基　　金：Supported by National Natural Science Foundation of China (NO:30300414)

摘　　要：目的研究融合自杀基因CDglyTK治疗喉癌。方法PCR扩增、酶切、连接、转化等构建质粒表达载体pcDNA3.1(-)CMV.CDglyTK,XhoⅠ/HindⅢ酶切鉴定,测序分析CDglyTK基因序列。建立稳定表达CDglyTK基因的Hep-2细胞株,RT-PCR及Western-blotting鉴定CDglyTK基因的表达。MTT法观察5-FC、GCV、5-FC+GCV对表达CDglyTK基因的Hep-2细胞生长的抑制作用。结果酶切和基因测序分析证明重组质粒含完整的CD及TK基因,RT-PCR从转染细胞总RNA中扩出707bp的预期片段,West-ern-blotting检测到该基因表达的59kDa的蛋白。表达CDglyTK基因的Hep-2细胞在5-FC、GCV、5-FC+GCV干预下生长受到抑制,5-FC与GCV联合有更强的杀伤效应。结论CDglyTK融合自杀基因可以成为基因治疗喉癌的有效方法。[Objective] To study the in vitro treatment of laryngeal cancer using suicide gene CDglyTK. [Methods] Plasmid pcDNA3.1（-）CMV.CDglyTK, constructed by PCR, enzyme digestion, ligation and transduction ete was verified by digesting of Xho Ⅰ/Hind Ⅲ and automatic sequence analysis, then it was introduced into Hep-2 cells by electroperation to yield cells expressing CDglyTK stably after selecting with G418 （400 μg/mL） for 14 days. The expression of CDglyTK mRNA in transfected Hep-2 cells was tested by RT-PCR.In vitro chemosensitivity of CDglyTK -expressing Hep-2 cells to 5-FC, GCV or 5-FC ＋GCV was detected by MTI＇ assay. [Results] The recombinant plasmid contained full-length coding region sequence of CD and TK gene. A anticipated 707 bp fragment was amplified from total RNA of CDglyTK-expressing Hep-2 cells by RT-PCR and a fusion protein of 59 kDa was detected in cell extract from transfected Hep-2 cells. In vitro study growth of CDglyTK-positive Hep-2 cells were inhibited by 5-FC, GCV or 5-FC ＋GCV respectively,and the antitumour effect of 5-FC ＋GCV is superior to 5-FC or GCV. [Conclusion] CDglyTK may be a candidate for treating human laryngeal cancer.

关 键 词：CDGLYTK 基因治疗 喉癌 

分 类 号：R767.1[医药卫生—耳鼻咽喉科]